Expression of the Receptor for Advanced Glycation End Products, a Target for High Mobility Group Box 1 Protein, and its Role in Chronic Recalcitrant Rhinosinusitis with Nasal Polyps

详细信息    查看全文

• 作者：Karolina Dzaman ; Miroslaw J. Szczepanski…
• 关键词：Nasal polyposis ; Innate immunity ; Chronic inflammation ; RAGE ; HMGB1
• 刊名：Archivum Immunologiae et Therapiae Experimentalis
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：63
• 期：3
• 页码：223-230
• 全文大小：1,238 KB
• 参考文献：Andersson U, Erlandsson-Harris H (2004) HMGB1 is a potent trigger of arthritis. J Intern Med 255:344-50View Article PubMed
  Andersson U, Tracey KJ (2004a) HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 30(3):627-37View Article PubMed
  Andersson UG, Tracey KJ (2004b) HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J Intern Med 255:318-19View Article PubMed
  Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139-62View Article PubMed
  Bassi R, Giussani P, Anelli V et al (2008) HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 87:23-3View Article PubMed
  Bellussi LM, Chen L, Chen D et al (2012) The role of high mobility group box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal polyposis. Acta Otorhinolaryngol Ital 32:386-92PubMed Central PubMed
  Bellussi LM, Iosif C, Sarafoleanu C et al (2013) Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? J Biol Regul Homeost Agents 27:791-04PubMed
  Chen D, Bellussi LM, Passali D et al (2013) LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro. Acta Otorhinolaryngol Ital 33:398-04PubMed Central PubMed
  Chen D, Mao M, Bellussi LM et al (2014) Increase of high mobility group box chromosomal protein 1 in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 4:453-62View Article PubMed
  Erlandsson Harris H, Andersson U (2004) Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34:1503-512View Article PubMed
  Fokkens WJ, Lund VJ, Mullol J et al (2012) EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50:1-2PubMed
  Gelardi M, Fiorella R, Fiorella ML et al (2009) Nasal-sinus polyposis: clinical-cytological grading and prognostic index of relapse. J Biol Regul Homeost Agents 23:181-88PubMed
  Lund VJ, Kennedy DW (1995) Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl 167:17-1PubMed
  Lund VJ, Kennedy DW (1997) Staging for rhinosinusitis. Otolaryngol Head Neck Surg 117(3 Pt 2):S35–S40View Article PubMed
  Mantell LL, Parrish WR, Ulloa L (2006) Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25:4-1View Article PubMed
  Miszke A, Sanokowska E (1995) Cytology of nasal polyps. Otolaryngol Pol 49:225-30PubMed
  Norlander T, Westrin KM, Fukami M et al (1996) Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages. Laryngoscope 106(2 Pt 1):196-03View Article PubMed
  Ostberg T, Kawane K, Nagata S et al (2010) Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 62:2963-972View Article PubMed
  Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209View Article PubMed Central PubMed
  Raucci A, Palumbo R, Bianchi ME (2007) HMGB1: a signal of necrosis. Autoimmunity 40:285-89View Article PubMed
  Reh DD, Wang Y, Ramanathan M Jr et al (2010) Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 24:105-09View Article PubMed Central PubMed
  Schierbeck H, Lundback P, Palmblad K et al (2011) Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 17:1039-044View Article PubMed Central PubMed
  Shim EJ, Chun E, Lee HS et al (2012) The role of high-mobility group box-1 (HMGB1) in the pathogenesis of asthma. Clin Exp Allergy 42:958-65PubMed
  Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367-88View Article PubMed
  Singh VP, Bali A, Singh N et al (2014) Advanced Glycation end products and diabetic complications. Korean J Physiol Pharmacol 18:1-4View Article PubMed Central PubMed
  Sirois CM, Jin T, Miller AL et al (2013) RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med 210:2447-463View Article PubMed Central PubMed
  Szczepanski MJ, Czystowska M, Szajnik M et al (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105-113View Article PubMed Central PubMed
  Tarchalska-Krynska B, Zawisza E, Samolinski B (1993) Cytograms of nasal mucosa in seasonal and perennial allergic rhinitis. Pneumonol Alergol Pol 61:373-76PubMed
  Ulloa L, Messmer D (2006) High-m
• 作者单位：Karolina Dzaman (1)
  Miroslaw J. Szczepanski (1) (3)
  Marta Molinska-Glura (2)
  Antoni Krzeski (1)
  Mariola Zagor (1)
  
  1. Division of Dentistry, Department of Otolaryngology, Medical University of Warsaw, Stepinska 19/25, 00-739, Warsaw, Poland
  3. Department of Clinical Immunology, University of Medical Sciences, Poznan, Poland
  2. Department of Computer Science and Statistics, University of Medical Sciences, Poznan, Poland
  
• 刊物主题：Immunology; Pharmacology/Toxicology;
• 出版者：Springer Basel
• ISSN：1661-4917

文摘

A receptor for advanced glycation end products (RAGE) and its ligand high mobility group box 1 (HMGB1) protein has been linked to several chronic diseases, and acts as a trigger for inflammation signaling. Here, we study RAGE and HMGB1 expression in chronic, recalcitrant rhinosinusitis with nasal polyps (CRSwNP) to determine its potential clinical significance, i.e., disease recurrence and severity. RAGE and HMGB1 expression in CRSwNP was evaluated by immunohistochemistry in epithelial cells of fresh sinonasal mucosa samples obtained from the patients diagnosed with recalcitrant CRSwNP (n?=?25) and normal control mucosa (NC) (n?=?26). RAGE and HMGB1 expression levels in tissues were correlated with disease severity assessed by nasal endoscopy, CT scan, number of previous sinus surgeries, allergy status and nasosinusal microbiology. RAGE and HMGB1 were moderately or strongly expressed in CRSwNP tissue. No or weak RAGE expression was found in NC. HMGB1 was equally strongly expressed in NC. We observed a strong correlation between RAGE and disease severity, recurrence, undergone operations, asthma and aspirin exacerbated respiratory disease (AERD). Elevated RAGE expression is associated with increased disease severity, as well as allergy and AERD in patients with recalcitrant CRSwNP. It is possible that the explanation for recurrent CRSwNP pathogenesis might be related to RAGE overexpression with subsequent sinus mucosa hyperproliferation, necessitating several operations.